Dipamoy Datta¹*, Raja Kundu², Subrata Chakraborty³, Pragnadyuti Mandal⁴ and Swapan Kumar Mondal¹

¹Department of Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata, India
²Computer Education Training Program, NICS Computer, Kolkata, India
³Department of Pathology, Saroj Gupta Cancer Centre and Research Institute, Kolkata, India
⁴Department of Pharmacology, Nil Ratan Sircar Medical College and Hospital, Kolkata, India

*Corresponding Author: Dipamoy Datta, Department of Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata, India. E mail: ddbmbg@gmail.com

Received: August 20, 2024; Published: October 09, 2024

Abstract

An individualized immunotherapeutic management of metastatic prostate cancer still remains a great challenge due to the existence of multifactorial complexities like immunosuppressive tumor microenvironment, influence of metastatic dissemination, lack of proper clinical responsiveness and its patient specific marked variations. The overall process of prostate cancer metastasis ranging from its epithelial mesenchymal transition (EMT) to distant metastatic colonization plays a leading role in development of immunosuppression in various ways. In this regard, different contributing factors in prostate cancer immunosuppression may include epithelial mesenchymal transition (EMT), metastatic signaling molecules, pre-metastatic colonization, tumor micro-environmental remodeling and cancer stem cells. Here, in this mini-review we particularly focus on important metastatic aspects, their mechanistic overviews and how they modulate acquisition of immunosuppressive phenotypes in advanced prostate cancer along with the key criteria needed to make the immunotherapy more individualized. Additionally, we also provides an in-depth assessment for most of the associated critical factors, like as pre-clinical model, predictive biomarker, clinical trial and patient selection criteria’s required for personalization of prostate cancer immunotherapies based on different immunosuppressive signaling routes.

 Keywords: Prostate Cancer; Personalized Treatment; Immunosuppression; Bone Metastasis; Epithelial Mesenchymal Transition (EMT)

References

1. Wong SK., et al. “Prostate Cancer and Bone Metastases: The Underlying Mechanisms”. International Journal of Molecular Sciences20 (2019): 2587.
2. Deng X., et al. “Recent advances in bone-targeted therapies of metastatic prostate cancer”. Cancer Treatment Review 40 (2014): 730-738.
3. Jin JK., et al. “Steps in prostate cancer progression that lead to bone metastasis”. International Journal of Cancer 128 (2011): 2545-2561.
4. Kessel A., et al. “Current management of metastatic castration-sensitive prostate cancer”. Cancer Treatment Research Communication28 (2021): 100384.
5. Datta D., et al. “A comprehensive mechanistic basis of prostate cancer advancement and its personalized implementation-bridging the gap: present state and future prospect”. Journal of Men’s Health 17 (2021): 18-35.
6. Rekoske BT., et al. “Immunotherapy for Prostate Cancer: False Promises or True Hope?” Cancer 122 (2016): 3598-3607.
7. Kfoury Y., et al. “Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment”. Cancer Cell 39 (2021): 1464-1478.e8.
8. Reinstein ZZ., et al. “Overcoming immunosuppression in bone metastases”. Critical Reviews in Oncology/Hematology117 (2017): 114-127.
9. Sharma P., et al. “Nivolumab plus Ipilimumab for metastatic castration-resistant prostate cancer: Preliminary analysis of patients in the CheckMate 650 trial”. Cancer Cell38 (2020): 489-499.e3.
10. Qi Z., et al. “Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment”. Nature Communication13 (2022): 182.
11. Ihle CL., et al. “Integrating the immune microenvironment of prostate cancer induced bone disease”. Molecular Carcinogenesis59 (2020): 822-829.
12. Kahkonen TE., et al. “Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis”. Cells 10 (2021): 1529.
13. Kolijin K., et al. “Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression”. Cancer Research78 (2018): 4671-4679.
14. Wu CT., et al. “Effect of tumor burden on tumor aggressiveness and immune modulation in prostate cancer: Association with IL-6 signaling”. Cancers (Basel)11 (2019): 992.
15. Hatakeyama S., et al. “Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study”. International Journal of Urology27 (2020): 610-617.
16. Su W., et al. “The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression”. Cancer Cell36 (2019): 139-155.e10.
17. Magnusson LU., et al. “Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment”. Prostate 76 (2015): 383-393.
18. Stultz J., et al. “How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer”. Prostate Cancer and Prostatic Diseases 24 (2021): 697-717.
19. Sanaei MJ., et al. “Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer”. Journal of Leukocyte Biology107 (2020): 43-56.
20. De-Souza PB., et al. “Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-β1”. Stem Cells34 (2016): 2536-2547.
21. Qin W., et al. “Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling”. Frontiers in Pharmacology8 (2017): 153.
22. Caputo S., et al. “Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis”. Frontiers in Immunology11 (2020): 1820.
23. Bilusic M., et al. “Immunotherapy of Prostate Cancer: Facts and Hopes”. Clinical Cancer Research 23 (2017): 6764-6770.
24. Bryant G., et al. “Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer”. International Journal of Molecular Sciences18 (2017): 1542.
25. Wilson BE., et al. “Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?”Cancer Cell38 (2020): 438-440.
26. Bou-Dargham MJ., et al. “Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy”. BMC Cancer20 (2020): 572.
27. Berish RB., et al. “Translational models of prostate cancer bone metastasis”. Nature Reviews Urology15 (2018): 403-421.
28. Park SH., et al. “Models of Prostate Cancer Bone Metastasis”. Methods in Molecular Biology 1914 (2019): 295-308.
29. Wang Y., et al. “Liquid biopsy in prostate cancer: current status and future challenges of clinical application”. Aging Male 24 (2021): 58-71.
30. Liu W., et al. “Circulating tumor cells in prostate cancer: Precision diagnosis and therapy”. Oncology Letter14 (2017): 1223-1232.
31. Wei ZJ., et al. “M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer”. Annals of Medicine53 (2021): 730-740.
32. Adamaki M., et al. “Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer”. Cancers (Basel) 13 (2021): 173.
33. Iuliani M., et al. “Current and Emerging Biomarkers Predicting Bone Metastasis Development”. Frontiers in Oncology10 (2020): 789.
34. Ottini A., et al. “Biomarker-driven immunotherapy for precision medicine in prostate cancer”. Peronalized Medicine 19 (2022): 51-66.
35. Wu YM.,et al. “Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer”. Cell 173 (2018): 1770-1782.e14.
36. Rizzo A., et al. “Is There a Role for Immunotherapy in Prostate Cancer?” Cells9 (2020): 2051.
37. Smits M., et al. “Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer”. Journal of Clinical Oncology 36 (2018): 248-248.
38. Barata P., et al. “Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA”. Journal for Immunotherapy of Cancer8 (2020): e001065.
39. Abida W., et al. “Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade”. JAMA Oncology5 (2018): 471-478.
40. Chan TA., et al. “Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic”. Annals of Oncology 30 (2019): 44-56.
41. Gao J., et al. “VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer”. Nature Medicine23 (2017): 551-555.
42. Subudhi SK., et al. “Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment”. Journal for Immunotherapy of Cancer9 (2021): e002919.
43. Gaudreau PO., et al. “The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements”. Biomarkers in Cancer8 (2016): 15-33.
44. Ma Z., et al. “Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications”. Cancer Medicine10 (2021): 5358-5374.
45. Asif S., et al. “Biomarkers for Treatment Response in Advanced Prostate Cancer”. Cancers (Basel)13 (2021): 5723.
46. Hirz T., et al. “Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analysis”. Nature Communication 14 (2023): 663.
47. Vidotto T., et al. “PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells”. Prostate 79 (2019): 969-979.
48. Ryan MJ., et al. “Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications”. Frontiers in Oncology9 (2019): 1287.
49. Chen JY., et al. “A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer”. Genomics 115 (2023): 110691.

Citation

Citation: Dipamoy Datta., et al. “The Involvement of Metastasis in Immunosuppression: A New Frontier in Prostate Cancer Personalized Immunotherapy”.Acta Scientific Medical Sciences 8.11 (2024): 25-40.

Copyright

Copyright: © 2024 Dipamoy Datta., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.